Search

Researchers from Binzhou Medical University in China conducted a study on the effectiveness and safety of combining hepatic arterial infusion chemotherapy (HAIC) with lenvatinib and tislelizumab for advanced hepatocellular carcinoma (HCC) with high tumor burden. The study included 162 treatment-naive patients with advanced HCC, and after propensity score matching, it was found that the group receiving HAIC showed significantly prolonged overall survival and progression-free survival compared to the group without HAIC. The researchers concluded that HAIC combined with lenvatinib and tislelizumab could be a promising treatment option for advanced HCC patients due to improved prognosis and acceptable safety. [Extracted from the article]

A study conducted at Fudan University in Shanghai, China, focused on anaplastic thyroid cancer (ATC) and the use of lenvatinib as a treatment option. The research found that targeting Cdk2 in combination with lenvatinib could be effective in treating lenvatinib-resistant ATC patients with high CDK2 expression. The study highlights the potential of a combination therapy strategy for improving clinical outcomes in ATC patients. The findings were published in Advanced Science and can be accessed online. [Extracted from the article]

A recent study conducted at Southwest Medical University in Sichuan, China, explored the efficacy and safety of combining envafolimab and lenvatinib for the treatment of unresectable hepatocellular carcinoma (HCC). The study included 36 patients, with 30 receiving the combination therapy. Results showed a median overall survival of 18.5 months and a manageable safety profile, with 76.7% of patients experiencing at least one treatment-related adverse event. The research concluded that the combination of envafolimab and lenvatinib demonstrates favorable anti-cancer activity for patients with unresectable HCC. [Extracted from the article]

A clinical trial, NCT06746961, is being conducted to evaluate the efficacy and safety of QL1706 plus lenvatinib as a second-line therapy for patients with metastatic esophageal squamous cell carcinoma after progression on immune checkpoint inhibitor therapy. The trial aims to assess various outcome measures, including overall survival, progression-free survival, objective response rate, duration of response, and adverse events. The study is set to enroll 49 participants and is scheduled for completion in August 2027. The trial is being conducted by The First Affiliated Hospital of Zhengzhou University. [Extracted from the article]

A study conducted by China Medical University and Hospital in Taichung, Taiwan, focused on the real-world experience of lenvatinib-based therapy in patients with advanced hepatocellular carcinoma (HCC). The study included 53 patients receiving lenvatinib monotherapy and 19 patients receiving lenvatinib plus immune checkpoint inhibitor combination therapy. Results showed that while patients receiving combination therapy had a greater treatment response, there were no significant survival differences between the two groups. The research concluded that incorporating albumin-bilirubin grade and neutrophil-lymphocyte ratio can help stratify survival outcomes in patients with unresectable HCC undergoing lenvatinib monotherapy. [Extracted from the article]

A prospective multicenter study, NCT06740370, focuses on treating hepatocellular carcinoma (HCC) with spontaneous rupture using transcatheter arterial chemoembolization (TACE) combined with Lenvatinib and a PD-1 inhibitor. This treatment aims to effectively inhibit the tumor and improve the prognosis of this subtype of HCC. The study, conducted in China, explores the efficacy and safety of this combined therapy as a first-line treatment for unresectable ruptured HCC. The trial is currently recruiting participants, with a primary completion date set for December 30, 2025. [Extracted from the article]

A recent study conducted at Southern Medical University in Guangzhou, China, focused on the development of a sensitive LC-MS/MS method for determining lenvatinib and its major metabolites in human plasma. Lenvatinib has shown effectiveness in treating advanced hepatocellular carcinoma (HCC), but its pharmacokinetic-pharmacodynamics behavior remains unclear. The study successfully validated a method for analyzing lenvatinib and its metabolites in plasma samples from HCC patients, providing a valuable tool for further pharmacokinetic-pharmacodynamics studies. This research was funded by various organizations and has been peer-reviewed, offering important insights into liver cancer treatment. [Extracted from the article]

Researchers at Believers Church Medical College in Kerala, India, have published new data on the use of Lenvatinib, a multiple receptor tyrosine kinase inhibitor approved by the FDA for treating certain types of cancer. The study highlights common adverse reactions associated with Lenvatinib, such as rash, myalgia, and hypertension, and emphasizes the need for caution in patients with specific medical conditions. The research also includes a case report of a patient who developed acral peeling skin syndrome following Lenvatinib therapy. For more information, readers can access the full article in the National Journal of Pharmacology and Therapeutics. [Extracted from the article]

A recent study conducted by researchers at the University of Padova in Italy focused on the disease course and treatment patterns of Acute Myeloid Leukemia (AML) with FLT3 mutations and myeloid sarcoma (MS). The study included 24 patients with FLT3-mutated AML and histologically confirmed MS, revealing that patients with this condition generally have a poor prognosis. However, the study found that FLT3 inhibitors, particularly gilteritinib, showed efficacy in treating FLT3-mutated MS, leading to longer survival times and high response rates. The research suggests that gilteritinib may have a role in treating MS, even in challenging sites like the central nervous system, and could potentially serve as a bridging therapy to allogenic stem cell transplantation. [Extracted from the article]

Researchers at Army Medical University conducted a study on the clinical efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and PD-1 antibody in treating intermediate-advanced hepatocellular carcinoma (HCC). The study involved 105 patients with intermediate-advanced HCC, showing an objective response rate (ORR) of 62.8% and a disease control rate (DCR) of 72.3%. The median overall survival (mOS) was not reached, and the median progression-free survival (mPFS) was 10.3 months. The researchers concluded that this triple therapy is a safe and effective treatment option for improving the prognosis of intermediate-advanced HCC. [Extracted from the article]

Researchers at Tianjin Medical University conducted a study to compare the effectiveness and safety of two common treatment regimens, Bevacizumab and sintilimab combined interventional treatment (BeSiIT) and Lenvatinib and sintilimab combined interventional treatment (LeSiIT), for intermediate-advanced hepatocellular carcinoma (HCC). The study included 127 patients and found that both groups showed comparable progression-free survival (PFS), overall survival (OS), and objective response rate (ORR), with manageable toxicity profiles. The research concluded that both treatment groups exhibited acceptable toxicities and comparable outcomes for intermediate-advanced HCC. [Extracted from the article]

A study conducted at Memorial Sloan-Kettering Cancer Center in New York City focused on the efficacy of lenvatinib plus pembrolizumab in treating advanced renal cell carcinoma. The combination treatment showed a robust objective response rate of 71% in treatment-naïve patients, with high 36-month overall survival rates across different response groups. The research concluded that the response to this combination therapy supports its use as a standard-of-care first-line treatment for patients with advanced renal cell carcinoma. [Extracted from the article]

Researchers at Albert Einstein Israelite Hospital in Sao Paulo, Brazil, have published a new report on liver cancer, specifically focusing on the treatment of unresectable hepatocellular carcinoma (HCC). The study discusses the use of combinations of lenvatinib, immune checkpoint inhibitors, and transarterial chemoembolization for patients with initially unresectable HCC, highlighting potential advancements in the field. This research has been peer-reviewed and is available in the World Journal of Gastrointestinal Oncology. For more information, readers can contact Pedro Luiz Serrano Uson Junior at Albert Einstein Israelite Hospital in Sao Paulo, Brazil. [Extracted from the article]

A recent study conducted at the Institute Gustave-Roussy in Villejuif, France, evaluated the efficacy of combining lenvatinib with ifosfamide and etoposide in children and young adults with relapsed osteosarcoma. The study, which included 81 patients, found that while the lenvatinib combination did not significantly improve progression-free survival compared to ifosfamide and etoposide alone, it highlighted the importance of international collaboration in clinical trials for patients with relapsed osteosarcoma. The research, which has been peer-reviewed, may provide valuable insights for future trial designs in this field. [Extracted from the article]

Researchers at Tongji Medical College in Wuhan, China, published a case report on the significant response of a 60-year-old female with Epstein-Barr-virus-associated intrahepatic cholangiocarcinoma (EBVaiCCA) to a combination therapy of pembrolizumab and lenvatinib. The patient showed an overall survival of 20 months, indicating a potential treatment option for advanced EBVaiCCA patients. This study highlights the importance of exploring the role of EBV as a biomarker in response to immunotherapy for intrahepatic cholangiocarcinoma. [Extracted from the article]

A study from Kobe University in Japan explored the use of lenvatinib, a kinase inhibitor, as induction chemotherapy before radiotherapy in an 85-year-old woman with localized unresectable thymic carcinoma. The research suggests that lenvatinib may be a viable option for similar cases, providing new insights into the treatment of this rare malignancy. This peer-reviewed study offers valuable information for healthcare professionals and researchers interested in oncology and thymic cancer treatment options. [Extracted from the article]

A study conducted at Zhejiang University in Hangzhou, China, focused on developing a silk fibroin-based nanomedicine for the systemic treatment of hepatocellular carcinoma (HCC). The research aimed to enhance the effectiveness of tyrosine kinase inhibitors (TKIs) in treating HCC by improving their circulation, tumor targeting, and infiltration. The study concluded that the silk fibroin-based approach shows promise in advancing systemic therapy for HCC due to its low immunogenicity and high reproducibility. The research has been peer-reviewed and published in ACS Applied Materials & Interfaces. [Extracted from the article]

Researchers from Tel Aviv University conducted a study on the impact of hepatitis B virus (HBV) infection on the efficacy of sorafenib and lenvatinib, tyrosine kinase inhibitors used in hepatocellular carcinoma (HCC) treatment. The study found that HBV-infected cells showed resistance to both drugs, affecting cell cycle gene expressions and critical signaling pathways. While sorafenib decreased pERK and pAKT levels in HBV-infected cells, lenvatinib increased these levels. The research highlights the need to understand the differing resistance mechanisms of these medications in HBV-infected hepatoma cells. [Extracted from the article]

Researchers from Seoul National University College of Medicine have established and characterized mouse organoids to study metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma (HCC) and drug responses, particularly focusing on Lenvatinib resistance. The study found that multi-biotics, a fermented product, enhanced the response to Lenvatinib in HCC models, despite not reducing tumor burden. Transcriptomic analysis of drug-resistant organoids identified key pathways related to KRAS signaling, inflammation, and epithelial-mesenchymal transition (EMT), providing insights into potential targets for overcoming Lenvatinib resistance in MASH-related HCC. This research offers a valuable model for further therapeutic studies in liver cancer treatment. [Extracted from the article]

A study conducted at the First Hospital of Jilin University explores the use of ultrasound-triggered nano delivery of lenvatinib for selective immunotherapy treatment against hepatocellular carcinoma (HCC). Lenvatinib, a receptor tyrosine kinase inhibitor, is utilized in this research to trigger robust systemic anti-tumour immune responses in a H22 tumour model, resulting in a high tumour suppression rate and potential cure for some mice. The study highlights a novel strategy combining lenvatinib and ultrasound therapy for enhanced HCC immunotherapy, offering promising results for future treatment options. [Extracted from the article]

A recent study conducted at Shanghai Jiao Tong University explored the use of neoadjuvant therapy with pembrolizumab and lenvatinib in patients with hepatocellular carcinoma before liver transplant. The study found that this combination therapy was safe and feasible, leading to significantly better recurrence-free survival rates for patients exceeding the Milan criteria. Despite the small sample size, this research provides valuable insights for future studies on neoadjuvant therapy in liver transplant recipients. [Extracted from the article]

Researchers at Second Military Medical University published a case report and literature review on the association between lenvatinib, a drug used in treating advanced hepatocellular carcinoma, and renal microvascular complications. The study focused on a 68-year-old male patient with HCC who experienced renal adverse effects post-lenvatinib initiation, leading to renal microvascular damage. The findings underscore the importance of vigilant renal monitoring and personalized therapeutic strategies for patients undergoing lenvatinib treatment, especially those with pre-existing risk factors. Early intervention and tailored treatment plans are crucial in preventing severe renal impairment in advanced HCC patients. [Extracted from the article]

A study conducted at Englewood Hospital and Medical Center in New Jersey explored the use of pembrolizumab and lenvatinib in treating endometrial carcinosarcoma, a rare and aggressive subtype of uterine malignancy. The research, which included eight patients, found improvements in progression-free survival and overall survival with manageable side effects, suggesting the potential efficacy of this treatment as a second-line option after platinum-based chemotherapy. The study was published in the European Journal of Gynaecological Oncology and provides valuable insights into this treatment approach for endometrial carcinosarcoma. [Extracted from the article]

A Phase I/II clinical trial, NCT06682780, is being conducted to evaluate the safety and tolerability of LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with advanced solid tumours. The study aims to determine the recommended phase 2 dose (RP2D) or Maximum Tolerated Dose (MTD) for LM-2417. The trial is not yet recruiting participants and is expected to enroll 320 individuals with advanced solid tumors. The study is being conducted in China and is led by LaNova Medicines Limited. [Extracted from the article]

Researchers at Sun Yat-sen University Cancer Center conducted a study on liver cancer patients receiving Lenvatinib and Pembrolizumab, focusing on the CRAFITY score as a prognostic indicator. The study included 228 patients with hepatocellular carcinoma, categorizing them based on their CRAFITY scores. Results showed that the CRAFITY score was significantly associated with overall survival, making it a valuable predictor for patients undergoing this treatment. The study concluded that the CRAFITY score is an important prognostic indicator for hepatocellular carcinoma patients receiving Lenvatinib and Pembrolizumab. [Extracted from the article]

A recent study conducted at Hannover Medical School compared the real-world effectiveness of lenvatinib (LEN) to atezolizumab/bevacizumab (AZ/BV) in treating hepatocellular carcinoma (HCC) patients. The study included 412 patients across 18 university hospitals in Europe and found that both treatments are viable first-line options for HCC. However, patients treated with AZ/BV had a longer median progression-free survival, but also a higher risk of hepatic decompensation in cases of impaired baseline liver function. The study emphasizes the importance of careful monitoring and the need for future trials to distinguish between different liver diseases. [Extracted from the article]

Research from the University of Bonn explores the immunomodulatory effects of different FLT3 inhibitors on dendritic cells, which play a crucial role in immune responses. The study focused on midostaurin, gilteritinib, and quizartinib, revealing that midostaurin had a dose-dependent immunosuppressive effect by inhibiting key signaling pathways. These findings could inform optimal maintenance therapy for FLT3-positive AML patients post-allogeneic hematopoietic stem cell transplantation to prevent complications like Graft versus Host disease. [Extracted from the article]

A recent study compared the effectiveness of transcatheter arterial chemoembolization plus Sorafenib versus transcatheter arterial chemoembolization plus Lenvatinib for intermediate hepatocellular carcinoma (HCC) patients. The study found that TACE-S was more effective in terms of overall survival (OS) compared to TACE-L, with no significant difference in progression-free survival (PFS) between the two groups. The research aimed to address the lack of comparative studies for these two regimens in intermediate HCC patients, providing valuable insights for future treatment approaches. [Extracted from the article]

A study conducted at Ningbo University in Zhejiang, People's Republic of China, focused on the roles of Lenvatinib in treating advanced hepatocellular carcinoma (HCC) and its resistance mechanisms. The research highlighted the dysregulation of crucial signaling pathways, noncoding RNA, and RNA modifications associated with Lenvatinib resistance. The study also discussed the potential of combination therapy to enhance the efficacy of Lenvatinib in treating advanced HCC. This peer-reviewed research provides new insights into Lenvatinib resistance and treatment strategies for advanced liver cancer. [Extracted from the article]

A recent meta-analysis conducted by researchers at Hamilton Health Sciences in Canada evaluated the efficacy and safety of lenvatinib, both as a monotherapy and in combination with other tyrosine kinase inhibitors, for the treatment of metastatic renal cell carcinoma (RCC). The study found that lenvatinib, especially when used in combination therapies, significantly improved progression-free survival (PFS) and overall survival (OS) compared to other tyrosine kinase inhibitors. While lenvatinib was associated with various adverse events, its safety profile was comparable to other TKIs. This research provides valuable insights into the potential benefits of lenvatinib in treating metastatic RCC. [Extracted from the article]

Researchers from Huazhong University of Science and Technology in Wuhan, China, have identified mechanisms of resistance to lenvatinib in liver cancer. Lenvatinib, a multikinase inhibitor, has shown superior efficacy in treating hepatocellular carcinoma compared to sorafenib. The study highlights the importance of understanding and overcoming drug resistance to improve treatment outcomes for liver cancer patients. This research, supported by the National Natural Science Foundation of China and the Natural Science Foundation of Hubei Province, provides valuable insights into potential strategies for sensitizing liver cancer cells to lenvatinib therapy. [Extracted from the article]

A retrospective cohort study conducted at Tsinghua University in Beijing, China, compared the efficacy of a novel treatment regimen for advanced biliary tract cancer (BTC) with standard chemotherapy options. The study found that the novel regimen, which included hepatic artery infusion chemotherapy with mFOLFOX-HAIC, lenvatinib, and PD-1 inhibitors, demonstrated superior progression-free survival and overall survival compared to standard regimens. The research concluded that the new treatment appears to be safe and well-tolerated for advanced BTC patients. [Extracted from the article]

Researchers from the Ministry of Health of Russia have published new findings on the treatment of endometrial cancer, highlighting the challenges faced by patients with advanced forms of the disease. The study emphasizes the importance of tailored treatment approaches based on tumor types, with a focus on a combination of pembrolizumab and lenvatinib as a second-line therapy for specific types of endometrial cancer. This research offers hope for improved outcomes and long-term disease control for patients with advanced endometrial cancer. [Extracted from the article]

Researchers from Nagasaki University have submitted a patent application for a cancer treatment agent that combines an immune checkpoint inhibitor, interleukin-18 (IL-18), and a T cell growth factor to address intractable cancers, particularly those resistant to standard therapies. The combination of these agents showed promising results in reducing tumor size and increasing production of antitumor cytokines in a mouse model of liver cancer. The patent application aims to provide a novel and effective immunotherapeutic approach for challenging cancers, offering potential benefits for patients with inflammation-related cancers. [Extracted from the article]

A study conducted by the University of Pennsylvania examined the overall survival rates of United States veterans with unresectable hepatocellular carcinoma (uHCC) who received different treatments. The research found that patients who received atezolizumab plus bevacizumab had longer overall survival compared to those who received sorafenib or lenvatinib. The study also noted that the survival outcomes were consistent across racial and ethnic subgroups. This study provides valuable insights into the effectiveness of different treatments for uHCC in veterans. [Extracted from the article]

A study conducted at Sun Yat-sen University Cancer Center in China compared the efficacy and safety of PD-L1 antibodies versus PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma. The study found that PD-L1 antibodies may be a preferable companion in the combination therapy, showing a higher objective response rate and a relatively lower incidence of severe adverse events compared to PD-1 antibodies. Further prospective studies with a larger patient population are recommended to validate these findings. [Extracted from the article]

Researchers at National Tsing-Hua University in Hsinchu, Taiwan, have conducted a study on liver cancer and the resistance to tyrosine kinase inhibitors (TKIs) like sorafenib and lenvatinib. The study utilized a 3D microfluidic chip model to investigate the role of cancer-associated fibroblasts (CAFs) in inducing drug resistance in hepatoma cells. The findings suggest that AHSG and CLEC3B may mediate fibroblast-induced resistance to TKIs, providing insights for potential approaches to enhance liver cancer treatment effectiveness. This research has been peer-reviewed and offers valuable information on improving therapies for liver cancer. [Extracted from the article]

A recent study conducted at Cedars Sinai Medical Center in Los Angeles, California, examined cost-sharing trends for commercially insured patients prescribed lenvatinib (Lenvima), a kinase inhibitor used in cancer treatment. The study found that insurance covered the majority of the drug costs, with 75% of patients paying $100 or less per month out of pocket. The researchers suggest that health systems and drug manufacturers should identify patients with high out-of-pocket costs and provide financial assistance to ensure access to these beneficial drugs. The study also highlighted the need for value-based payment models and drug pricing reform to address high drug costs. [Extracted from the article]